文献速递肾癌与肾肿瘤

长链非编码RNA标签在局限性透明细胞肾细胞癌中的预后价值

Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
PubMed 文献 · Eur Urol · 2018-08-22

基于TCGA的444例I-III期ccRCC RNA-seq数据,用LASSO Cox回归在222例训练集中构建四lncRNA分类器RCClnc4,在222例内部验证集、88例日本队列及1869例中国RT-PCR队列中验证。RCClnc4可独立分层高低风险,多因素HR为1.34-1.89,均值c-index 0.72优于TNM和SSIGN,联合临床特征后提升至0.75。

要点

  • RCClnc4由四个lncRNA构成,可独立于临床病理因素对I-III期ccRCC进行风险分层。
  • RCClnc4预后准确性均值c-index 0.72,高于TNM 0.62和SSIGN 0.64。
  • 与TNM或SSIGN联合后均值c-index提升至0.75,并可识别高危I期和低危II-III期患者。

核心结论

  • RCClnc4分类器是有前景的预后工具,可预测I-III期ccRCC患者生存,联合临床病理参数可提高风险评估准确性以指导临床管理。

研究设计与样本

  • 基于TCGA 444例I-III期ccRCC肿瘤的RNA-seq数据,在222例随机训练集中用LASSO Cox回归构建四lncRNA分类器,在剩余222例内部验证集验证。
  • 外部验证包括日本队列88例I-III期ccRCC患者,以及另外三个独立集共1869例中国I-III期ccRCC患者的RT-PCR数据。

主要发现

  • RCClnc4基于四个lncRNA:ENSG00000255774、ENSG00000248323、ENSG00000260911和ENSG00000231666。
  • 在RNA-seq和RT-PCR数据集中,RCClnc4标签在跨亚群和亚群内均将患者显著分层为高风险与低风险组。
  • 多因素分析调整临床和病理因素后,RCClnc4仍为独立预后因素,风险比范围1.34(95%CI 1.03-1.75;p=0.028)至1.89(95%CI 1.55-2.31;p<0.001)。
  • RCClnc4均值c-index为0.72,高于TNM均值c-index 0.62和SSIGN评分均值c-index 0.64。
  • 与临床特征整合后,TNM+RCClnc4和SSIGN+RCClnc4均值c-index均为0.75,在所有数据集中预后准确性提高。

关键数值与推荐

  • RCClnc4分类器可识别临床上显著数量的高危I期和低危II-III期患者。

临床怎么用

  • RCClnc4可作为I-III期ccRCC术后风险分层工具,联合TNM或SSIGN评分提高预后评估准确性。
  • 该分类器有助于识别高危I期和低危II-III期患者,辅助临床管理和治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long non-coding RNAs (lncRNAs) can be used as prognostic biomarkers in many types of cancer. OBJECTIVE: We sought to establish an lncRNA signature to improve postoperative risk stratification for patients with localized clear cell renal cell carcinoma (ccRCC). DESIGN, SETTING, AND PARTICIPANTS: Based on the RNA-seq data of 444 stage I-III ccRCC tumours from The Cancer Genome Atlas project, we built a four-lncRNA-based classifier using the least absolute shrinkage and selection operation (LASSO) Cox regression model in 222 randomly selected samples (training set) and validated the classifier in the remaining 222 samples (internal validation set). We confirmed this classifier in an external validation set of 88 patients with stage I-III ccRCC from a Japan cohort and using quantitative reverse transcription polymerase chain reaction (RT-PCR) in another three independent sets that included 1869 patients from China with stage I-III ccRCC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Univariable and multivariable Cox regression, Harrell's concordance index (c-index), and time-dependent receiver operating characteristic curves were used to evaluate the association of the classifier with overall survival, disease-specific survival, and disease-free survival. RESULTS AND LIMITATIONS: Using the LASSO Cox regression model, we built a classifier named RCClnc4 based on four lncRNAs: ENSG00000255774, ENSG00000248323, ENSG00000260911, and ENSG00000231666. In the RNA-seq and RT-PCR data sets, the RCClnc4 signature significantly stratified patients into high-risk versus low-risk groups in terms of clinical outcome across and within subpopulations and remained as an independent prognostic factor in multivariate analyses (hazard ratio range, 1.34 [95% confidence interval {CI}: 1.03-1.75; p=0.028] to 1.89 [95% CI, 1.55-2.31; p<0.001]) after adjusting for clinical and pathologic factors. The RCClnc4 signature achieved a higher accuracy (mean c-index, 0.72) than clinical staging systems such as TNM (mean c-index, 0.62) and the stage, size, grade, and necrosis (SSIGN) score (mean c-index, 0.64), currently reported prognostic signatures and biomarkers for the estimation of survival. When integrated with clinical characteristics, the composite clinical and lncRNA signature showed improved prognostic accuracy in all data sets (TNM + RCClnc4 mean c-index, 0.75; SSIGN + RCClnc4 score mean c-index, 0.75). The RCClnc4 classifier was able to identify a clinically significant number of both high-risk stage I and low-risk stage II-III patients. CONCLUSIONS: The RCClnc4 classifier is a promising and potential prognostic tool in predicting the survival of patients with stage I-III ccRCC. Combining the lncRNA classifier with clinical and pathological parameters allows for accurate risk assessment in guiding clinical management. PATIENT SUMMARY: The RCClnc4 classifier could facilitate patient management and treatment decisions.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Qu L, Wang ZL, Chen Q, et al. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. Eur Urol. 2018. PMID: 30143382. doi:10.1016/j.eururo.2018.07.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。